Experts Debate Clinical Sequencing's Short- and Long-Term Impact on Dx, Therapeutics, Patient Health

"Next-gen sequencing is going to turn diagnostics completely upside down and on its head," Richard Resnick, CEO of GenomeQuest, said at a recent panel discussion on next-gen sequencing-based diagnostics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.